narmac, yep it would be.

One thing I keep forgetting to mention is that the Beacon NPV of $8.55 was based on a market penetration of 2%. The seems so remarkably low and of apabetalone does only the CVD, DM low HDL market the penetration will go way beyond 2% I think.

If Don gets the funding in place, hopefully without racing too much further toward to the bottom in terms of the deal structure, we might see some movement, at least I hope. If he races further to the bottom I will lose far more faith in Don's ability to run this company.

It's time to enjoy the Super Bowl.

Cheers

Toinv